Phase II/III clinical trial of anti-rheumatoid arthritis drug Kevzara for COVID-19 is to be conducted soon
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SDepartment of Health and Human Services Office for Preparedness and Response (ASPR) will support Regeneron Pharmaceuticals in conducting A COVID-19 clinical trial to assess the effectiveness and safety of Kevzara's treatment of criticalLY critical COVID-19 patientsKevzara is currently approved by the U.SFood and Drug Administration (FDA) for the treatment of rheumatoid arthritis (RA)patients with COVID-19 are at risk of developing severe respiratory failure, which may be partly dyed by elevated levels of a range of pro-inflammatory molecules, including leukade-6 (IL-6)Kevzara is an all-human monoclonal antibody that binds to IL-6 receptors on normal cells and improves the patient's prognosis by reducing severe inflammatory responsesKevzara was developed by Regeneron and SanofiDr Rick ABright, DIRECTOR OF BARDA, said: "We are working with private companies to accelerate the development of COVID-19 treatmentsBy reusing the currently approved products, we may be able to accelerate the delivery of treatments."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
